Neurana Pharmaceuticals to Participate at William Blair Biotech Conference
SAN DIEGO, July 12, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced participation at the William Blair Biotech Focus Conference. The conference takes place virtually July 14-15th. Presentations will be available for registered attendees via the William Blair conference site.
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. For additional information, please visit www.neuranapharma.com.
View original content:https://www.prnewswire.com/news-releases/neurana-pharmaceuticals-to-participate-at-william-blair-biotech-conference-301328360.html
SOURCE Neurana Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba's Amap Introduces ABot-Recon, Reconstructing 10,000-Frame-Scale 3D Scenes From Just 12 Frames in Real Time
- Start of Day Message
- Ackermans & van Haaren recorded a strong first half of 2026, with a net profit of EUR 339.6 million (+24%).
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share